BIOMAT Database Logo BIOMAT Database Logo

Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. 1993

R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Pharmaceuticals Division, CIBA-GEIGY Corporation, Summit, NJ 07901.

Serotonin 1a and serotonin-2 receptors are implicated in anxiety. Serazepine (CGS-15040A, (R,S)-1,3,4,16b-Tetrahydro-2-methyl-2H,10H-indolo[2,1-c] Pyrazino-[1,2-a][1,4] benzodiazepine-16-carboxylic acid, methyl ester hydrochloride]) is a representative of a novel pentacyclic ring system containing a stabilized indole. In chemical assays it was a highly specific inhibitor of serotonin (5-HT2) binding, and it was active in preliminary preclinical assays of anxiolytic potential. This multicenter trial of CGS-15040A in patients with generalized anxiety disorder demonstrated clinical anxiolytic effects consistent with established preclinical effects. Doses greater than or equal to 10 mg reduced Hamilton Anxiety Scale scores. However, the dose-response relationship was nonlinear. Effects appeared primarily related to the psychic components of anxiety.

UI MeSH Term Description Entries
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001008 Anxiety Disorders Persistent and disabling ANXIETY. Anxiety Neuroses,Anxiety States, Neurotic,Neuroses, Anxiety,Anxiety Disorder,Anxiety State, Neurotic,Disorder, Anxiety,Disorders, Anxiety,Neurotic Anxiety State,Neurotic Anxiety States,State, Neurotic Anxiety,States, Neurotic Anxiety
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine

Related Publications

R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry.
January 2002, The Journal of clinical psychiatry,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder.
February 1995, Journal of clinical psychopharmacology,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Serotonin-induced vasoconstriction in rabbit femoral artery: mediation by both 5-HT2 serotonergic and alpha 1-adrenoceptors.
June 1996, Journal of cardiovascular pharmacology,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
The paradox of relaxation training: Relaxation induced anxiety and mediation effects of negative contrast sensitivity in generalized anxiety disorder and major depressive disorder.
December 2019, Journal of affective disorders,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Post-stroke changes in cortical 5-HT2 serotonergic receptors.
December 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors.
August 1997, European journal of pharmacology,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Evidence for 5-HT2 receptor mediation in quipazine anorexia.
January 1990, Psychopharmacology,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder.
February 1989, Psychiatry research,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
January 1985, Journal of cardiovascular pharmacology,
R J Katz, and P S Landau, and M Lott, and A Bystritsky, and B Diamond, and R Hoehn-Saric, and M Rosenthal, and C Weise
[Generalized anxiety disorder].
January 2003, Ryoikibetsu shokogun shirizu,
Copied contents to your clipboard!